Sangamo Biosciences (NASDAQ: SGMO) reported Q3 EPS of ($0.27), $0.02 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $2.8 million versus the consensus estimate of $4.24 million.

For earnings history and earnings-related data on Sangamo Biosciences (SGMO) click here.